Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/19984
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSastre, J
dc.contributor.authorDíaz-Beveridge, R
dc.contributor.authorGarcía-Foncillas, J
dc.contributor.authorGuardeño, R
dc.contributor.authorLópez, C
dc.contributor.authorPazo, R
dc.contributor.authorRodriguez-Salas, N
dc.contributor.authorSalgado, M
dc.contributor.authorSalud, A
dc.contributor.authorFeliu, J
dc.date.accessioned2019-06-28T12:44:39Z-
dc.date.available2019-06-28T12:44:39Z-
dc.date.issued2015-12
dc.identifier.citationClin Transl Oncol.2015 Dec;(17)12:988-95
dc.identifier.urihttps://hdl.handle.net/20.500.12530/19984-
dc.description.abstractHepatocellular carcinoma (HCC) represents the second leading cause of cancer-related death worldwide. Surveillance with abdominal ultrasound every 6 months should be offered to patients with a high risk of developing HCC: Child-Pugh A-B cirrhotic patients, all cirrhotic patients on the waiting list for liver transplantation, high-risk HBV chronic hepatitis patients (higher viral load, viral genotype or Asian or African ancestry) and patients with chronic hepatitis C and bridging fibrosis. Accurate diagnosis, staging and functional hepatic reserve are crucial for the optimal therapeutic approach. Characteristic findings on dynamic CT/MR of arterial hyperenhancement with "washout" in the portal venous or delayed phase are highly specific and sensitive for a diagnosis of HCC in patients with previous cirrhosis, but a confirmed histopathologic diagnosis should be done in patients without previous evidence of chronic hepatic disease. BCLC classification is the most common staging system used in Western countries. Surgical procedures, local therapies and systemic treatments should be discussed and planned for each patient by a multidisciplinary team according to the stage, performance status, liver function and comorbidities. Surgical interventions remain as the only curative procedures but both local and systemic approaches may increase survival and should be offered to patients without contraindications.
dc.language.isoeng
dc.rightsopenAccess-
dc.subjectAblative therapies
dc.subjectGuidelines
dc.subjectHepatocellular carcinoma
dc.subjectSorafenib
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshCombined Modality Therapy
dc.subject.meshDisease Management
dc.subject.meshEarly Detection of Cancer
dc.subject.meshHumans
dc.subject.meshLiver Neoplasms
dc.subject.meshMedical Oncology
dc.subject.meshNeoplasm Staging
dc.subject.meshPractice Guidelines as Topic
dc.subject.meshPrognosis
dc.subject.meshSocieties, Medical
dc.titleClinical guideline SEOM: hepatocellular carcinoma.
dc.typeArtículo
dc.identifier.pubmedID26607931
dc.format.volume17
dc.format.page988-95
dc.identifier.e-issn1699-3055
dc.identifier.journalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.identifier.doi10.1007/s12094-015-1451-3
dc.format.number12
dc.identifier.pmcPMC4689753
dc.pubmedtypeJournal Article
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
PMC4689753.pdf1.3 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.